The Aranjuez factory reduces its accident rate by 9%

En el ejercicio 2020


In 2020, the Ercros factory in Aranjuez reduced its accident frequency rate and improved the quality of its products.

Specifically, the general accident frequency index – which measures accidents between internal and external personnel (with and without sick leave) for every million hours worked – fell by 9% compared to the previous year.

In terms of quality, between 2019 and 2020, the Aranjuez factory reduced its complaint rate by 16%. This index measures the number of tons of products affected by customer complaints about the number of tons sold.

This factory also experienced improvements in the environmental field: compared to the average of the last five years, the factory reduced its emissions index by 3.2%, which measures the substances emitted into the air and water and the generation of waste.

The Aranjuez center has certified occupational safety management according to ISO 45001, quality management according to ISO 9001 and environmental management according to ISO 14001; and verified its CO2 emissions in accordance with the ISO 14064 standard. Likewise, it is registered in the European environmental management and audit register EMAS.

Ercros' performance in all aspects of sustainability has earned it the Platinum classification, awarded by the international EcoVadis rating, obtaining a score of 81 out of 100; With this score, Ercros is among the 1% with the best compliance with ESG criteria (environmental, social and governance) of the 75,000 companies evaluated. Likewise, the company has been certified as a CSR Company in the Excellence category, by the Responsible Care program of the global chemical sector.

The Aranjuez factory makes up the Ercros pharmacy division. This center is intended to manufacture active pharmaceutical ingredients (APIs), mainly from the family of antibiotics. The factory directly employs 211 people and in 2020 it had a turnover of 58 million euros. 92% of sales were for export, mainly to the US, EU, Middle East and North Africa. It is the second world manufacturer of fusidic acid and the third of fosfomycin.